Hongyao Liu

State Key Laboratory Of Biotherapy
Chengdu, 610041, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Design, synthesis, and biological evaluation of ALK5 PROTAC degraders for pulmonary fibrosis.

Design, synthesis, and biological evaluation of ALK5 PROTAC degraders for pulmonary fibrosis.

Journal: Bioorganic chemistry

Published: February 06, 2026

Huangqi Guizhi Wuwu Decoction attenuates bleomycin-induced pulmonary fibrosis via modulating TGF-β/Smad and cell-cycle: Integrated transcriptomics, network pharmacology and experimental validation.

Huangqi Guizhi Wuwu Decoction attenuates bleomycin-induced pulmonary fibrosis via modulating TGF-β/Smad and cell-cycle: Integrated transcriptomics, network pharmacology and experimental validation.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: October 31, 2025

Design, synthesis, and biological evaluation of a potent and orally bioavailable FGFRs inhibitor for fibrotic treatment.

Design, synthesis, and biological evaluation of a potent and orally bioavailable FGFRs inhibitor for fibrotic treatment.

Journal: European journal of medicinal chemistry

Published: October 25, 2024

BRD4: an effective target for organ fibrosis.

BRD4: an effective target for organ fibrosis.

Journal: Biomarker research

Published: July 05, 2024

Polyphyllin VI Ameliorates Pulmonary Fibrosis by Suppressing the MAPK/ERK and PI3K/AKT Signaling Pathways via Upregulating DUSP6.

Polyphyllin VI Ameliorates Pulmonary Fibrosis by Suppressing the MAPK/ERK and PI3K/AKT Signaling Pathways via Upregulating DUSP6.

Journal: Phytotherapy research : PTR

Published: May 30, 2024

Niclosamide - encapsulated lipid nanoparticles for the reversal of pulmonary fibrosis.

Niclosamide - encapsulated lipid nanoparticles for the reversal of pulmonary fibrosis.

Journal: Materials today. Bio

Published: October 13, 2023

Application and Study of ROCK Inhibitors in Pulmonary Fibrosis: Recent Developments and Future Perspectives.

Application and Study of ROCK Inhibitors in Pulmonary Fibrosis: Recent Developments and Future Perspectives.

Journal: Journal of medicinal chemistry

Published: March 20, 2023

Discovery of the novel Benzo[b]thiophene 1,1-dioxide derivatives as a potent STAT3 inhibitor against idiopathic pulmonary fibrosis.

Discovery of the novel Benzo[b]thiophene 1,1-dioxide derivatives as a potent STAT3 inhibitor against idiopathic pulmonary fibrosis.

Journal: European journal of medicinal chemistry

Published: October 07, 2022

Design, synthesis and biological evaluation of novel diarylacylhydrazones derivatives for the efficient treatment of idiopathic pulmonary fibrosis.

Design, synthesis and biological evaluation of novel diarylacylhydrazones derivatives for the efficient treatment of idiopathic pulmonary fibrosis.

Journal: European journal of medicinal chemistry

Published: August 09, 2022

Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro.

Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro.

Journal: Journal of advanced research

Published: July 21, 2022

An oral phenylacrylic acid derivative suppressed hepatic stellate cell activation and ameliorated liver fibrosis by blocking TGF-β1 signalling.

An oral phenylacrylic acid derivative suppressed hepatic stellate cell activation and ameliorated liver fibrosis by blocking TGF-β1 signalling.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: May 30, 2022

Discovery and evaluation of phenacrylanilide derivatives as novel potential anti-liver fibrosis agents.

Discovery and evaluation of phenacrylanilide derivatives as novel potential anti-liver fibrosis agents.

Journal: European journal of medicinal chemistry

Published: April 21, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026